According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma? READ MORE
Researchers have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy pembrolizumab.
A recent study found that multiple factors including insurance status, ethnicity, and individual providing the diagnosis are associated with delays in treatment for patients with melanoma.
An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma.
Recently published long-term survival data shows the benefits of combining two conventional therapies to treat patients with advanced melanoma.
Bristol-Myers Squibb’s immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.
Research in Review
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety.
Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days.
Central nervous system imaging is needed during programmed death 1 inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases.
Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress.
The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.